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Abstract The use of mouse blood as a model for human
blood is often considered in the development of clinically
relevant, gene expression-based disease biomarkers.
However, the ability to derive biologically meaningful
insights from microarray-based gene expression patterns in
mouse whole blood, as in human whole blood, is hindered
by high levels of globin mRNA. In order to characterize
the effects of globin reduction on gene expression of
peripheral mouse blood, we performed gene set enrich-
ment analysis on genes identified as expressed in blood via
microarray-based genome-wide transcriptome analysis.
Depletion of globin mRNA enhanced the quality of
microarray data as shown by improved gene expression
detection and increased sensitivity. Compared to genes
expressed in whole blood, genes detected as expressed in
blood following globin reduction were enriched for low
abundance transcripts implicated in many biological
pathways, including development, g-protein signaling, and
immune response. Broadly, globin reduction resulted in
improved detection of expressed genes that serve as
molecular binding proteins and enzymes in cellular
metabolism, intracellular transport/localization, transcrip-
tion, and translation, as well as genes that potentially
could act as biomarkers for diseases such as schizophrenia.
These significantly enriched pathways overlap consider-
ably with those identified in globin-reduced human blood
suggesting that globin-reduced mouse blood gene expres-
sion studies may be useful for identifying genes relevant
to human disease. Overall, the results of this investigation
provide a better understanding of the impact of reducing
globin transcripts in mouse blood and highlight the
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potential of microarray-based, globin-reduced, mouse
blood gene expression studies in biomarker development.
Introduction
Microarray-based gene expression profiling is a frequently
used and powerful tool in the search for molecular ‘‘fin-
gerprints’’ of specific diseases and thus the development of
clinically relevant biomarkers for those diseases. For
example, seminal investigations have considered the use of
large-scale gene expression analyses to classify disease
states (Alizadeh et al. 2000; Dyrskjot et al. 2003; Golub
et al. 1999), develop diagnostic and prognostic gene pro-
files (Mirnics et al. 2000; van‘t Veer et al. 2002; Welsh
et al. 2001), and characterize transcriptomic fingerprints of
drug efficacy and toxicity (Gunther et al. 2003). While
many of these landmark studies relied heavily on primary
tissue samples, recent investigations have focused on
peripheral blood, a more accessible tissue (Chao et al.
2008; Coppola et al. 2008; Glatt et al. 2005; Le-Niculescu
et al. 2009; Miller et al. 2007; Wang et al. 2005). Aside
from being relatively easy to obtain, many of the physio-
logical characteristics of blood cells suggest that peripheral
blood gene expression is a reasonable surrogate for specific
primary tissue gene expression and hence can be used in
the development of clinically meaningful expression-based
biomarkers for diseases whose molecular ‘‘lesions’’ are
associated with particular nonblood primary tissues (Fan
and Hegde 2005; Liew et al. 2006; Mohr and Liew 2007).
One limitation of current studies designed to correlate
blood gene expression patterns to primary tissue gene
expression patterns is that blood and tissue samples are
often not collected from the same set of individuals (Glatt
et al. 2005; Liew et al. 2006; Solmi et al. 2006; Sullivan
et al. 2006). The use of independent sources of blood and
nonblood tissue gene expression information limits inter-
pretability and generalizability of relevant studies and calls
into question any putative blood-based gene expression
biomarker panel for the diagnosis and treatment of a dis-
ease whose primary lesions are not in blood. Nonetheless,
it is often too difficult or even impossible to obtain blood
and primary tissue samples from the same living individ-
uals. The mouse provides one possible solution to this
dilemma.
Unlike human subjects, blood and primary tissue sam-
ples can be easily collected from the same living mouse
under highly controlled conditions. Intra- and interindi-
vidual variation introduced by gender, age, time of day,
genetic variation, and environment can be reduced in such
studies (Cobb et al. 2005; Leonardson et al. 2010; Radich
et al. 2004; Whitney et al. 2003), while clinically
acceptable and highly standardized protocols for blood
collection, RNA isolation, and globin reduction can be
employed to lessen technical, assay-induced variation
(Cobb et al. 2005; Debey et al. 2004, 2006). In addition,
the fact that many different isogenic strains of mice exist
suggests that given the clone-like nature of the mice
within such strains, it is possible to sample expression
patterns in different tissues from different individuals
within particular strains and test the expression patterns
for consistencies as though they were obtained from the
same individuals.
It is known that high levels of globin transcripts in the
blood can confound the accurate assessment of the
expression levels of genes in the blood (Wu et al. 2007), as
globin mRNA represents up to 70% of the total expressed
transcripts and consequently limits the ability to accurately
detect genes expressed at low levels in the blood. Thus,
globin reduction is often considered a necessary step in the
evaluation of whole-blood gene expression profiles via
microarrays. GLOBINclearTM, a commercially available
(Applied Biosystems/Ambion, Austin, TX) globin reduc-
tion protocol, has been shown to improve gene expression
detection sensitivity, remove up to 95% of a- and b-globin
mRNA, and diminish globin-specific expression patterns in
human whole-blood samples (Field et al. 2007; Liu et al.
2006; Whitley et al. 2005; Wright et al. 2008). GLOBIN-
clearTM is also advantageous for mouse studies in that it
has been specifically developed for the mouse (Whitley
et al. 2007).
In this article we describe a study designed to (1)
evaluate and characterize the effects of globin reduction on
whole-blood gene expression in different mouse strains, (2)
determine which pathways are enriched for genes that
appear to be heavily influenced by the confounding or
masking effects of globin in the blood, and (3) assess the
utility of globin-reduced mouse whole blood in the iden-
tification of potential biomarkers of human disease.
Materials and methods
Sample collection
All animal procedures were performed according to pro-
tocols approved by the University of California San Diego
Institutional Animal Care and Use Committee. Seven-
week-old male mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) (129S1/SvImJ, A/J, C57BL/
6 J, C3H/HeJ, DBA/2 J, and FVB/NJ) and individually
housed for 1 week prior to blood collection. All mice were
anesthetized using isoflurane in a fume hood and whole
blood was collected via cardiac puncture. The blood was
transferred to an EDTA tube and then TRIzol LS reagent
(Invitrogen, Carlsbad, CA) was immediately added (3:1
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TRIzol:blood) creating a solution in a 15-ml tube that was
stored at -80C for no more than 2 weeks.
Processing and globin reduction
The extraction of total RNA from the blood was performed
using the TRIzol reagent (Invitrogen) according to the
manufacturer’s instructions. Total RNA quantity and qual-
ity was assessed by spectrophotometer and the RNA 6000
Nano Chip kit (Agilent, Santa Clara, CA). a- and b-globin
mRNA were reduced from a portion of the total RNA
samples using the GLOBINclearTM Mouse/Rat kit (Ambi-
on) according to the manufacturer’s instructions, with the
recommended start quantity of 10 lg of total RNA.
Sample amplification and microarray analysis
Gene expression analysis was performed on all whole-blood
RNA and globin-depleted samples using Mouse 430 2.0
arrays (Affymetrix, Santa Clara, CA) containing 45,101
probe sets. Sample labeling, hybridization, and scanning
were performed as previously described (Zapala et al.
2005). Three biological replicate samples from independent
mice were prepared for each strain for a total of 18 mice. All
raw data is available on the NCBI Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo, GSE19282).
Data analysis
Data processing and analysis were performed using R
(http://www.R-project.org) and Bioconductor (http://www.
bioconductor.org) (Gentleman et al. 2004). Array images
were visually scanned for artifacts while quality control
reports (affyQCReport) (Parman and Halling 2008) were
assessed and determined to be acceptable under Affymetrix
guidelines (Affymetrix GeneChip Expression Analysis
Data Analysis Fundamentals). MAS5 detection calls were
obtained using the Bioconductor affy package (Gautier et al.
2004). MAS5 detection calls are used to determine whether
a particular probe set is detected above background. Only
probe sets called present (detection P\0.05) were utilized
for analysis. The associated false discovery rate (Benjamini
and Hochberg 1995) for a detection P value of 0.05 was
28.9 ± 11.3% over all arrays. To accommodate for false
discoveries, probe sets were filtered for those present across
all whole-blood or globin-reduced samples prior to gene set
enrichment analysis (McClintick and Edenberg 2006).
Gene set enrichment analysis
Probe sets that were present in all 18 samples were assigned
to two categories (whole-blood RNA or globin-reduced
RNA) (Supplementary Tables 1 and 2) and imported into
MetaCore (http://www.genego.com) for enrichment analy-
sis in GeneGo Pathway Maps, GeneGo Diseases by Bio-
markers (GeneGo, St. Joseph, MI), GO Processes, and GO
Molecular Functions. GeneGo Pathway Maps represent a
set of genes participating in a consecutive set of metabolic
signals, or metabolic transformations, confirmed as a whole
by experimental data or by inferred relationships. GeneGo
Diseases by Biomarkers are groups of genes implicated in
certain diseases based on classifications in Medical Subject
Headings (http://www.nlm.nih.gov/mesh/). The list of
genes represented on the Affymetrix Mouse 430 2.0 array
was used as a base gene list when calculating P values in the
MetaCore enrichment procedures. MetaCore (GeneGo)
uses a hypergeometric model to determine the significance
of enrichment (Falcon and Gentleman 2007).
Comparison to human whole-blood gene expression
and tissue gene expression
For mouse and human whole-blood gene expression com-
parisons, raw human whole-blood gene expression data
were downloaded from the Gene Expression Omnibus
(GSE2888, GSE 16728). MAS5 calls were obtained as
outlined above and filtered for orthologous probe sets
present in 80% or more of globin-reduced samples for each
study individually. Orthologous genes and their associated
Affymetrix probe sets were identified using Ensembl
Biomart (http://www.www.ensembl.org/biomart). Filtered
probe set lists (Supplementary Table 3) were imported into
MetaCore and tested for enrichment in GeneGo Pathway
Maps. The list of genes represented on the Affymetrix HG
U133A array was used as a base gene list when calculating
P values in the MetaCore enrichment procedures for
GSE2888 and GSE16728.
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Fig. 1 Boxplots of present calls in whole-blood RNA and globin-
reduced blood RNA samples. The boxes represent the lower quartile
through the upper quartile, while the whiskers extend to 1.5 times the
interquartile range. Open circles denote outliers. A bold line denotes
the median. WB whole-blood RNA, GR globin-reduced blood RNA
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Results
Probe detection and microarray sensitivity following
globin reduction
Consistent with previously published study results, reduc-
tion of globin mRNA in mouse whole blood resulted in
a consistent increase in the number of probe sets detected
and improved microarray sensitivity, particularly for
low-abundance genes. The average number of present calls
in globin-reduced samples was 12,411 ± 1904 compared to
5840 ± 944 in untreated samples (Fig. 1), while 5383
probe sets were present across all samples following globin
reduction in contrast to 1791 present probe sets in whole-
blood RNA. Of the probe sets present across all arrays
(n = 5400), 3609 probe sets were unique to globin-reduced
RNA, 17 to whole-blood RNA, and 1774 were common to
both whole-blood and globin-reduced RNA. Greater than
Table 1 Distribution of probe sets detected in (1) globin-reduced samples only, (2) whole-blood samples only, or (3) both whole-blood and
globin-reduced samples across all detectable probes (n = 5400)
Percentile Globin-reduced only (total = 3609) Whole-blood only (total = 17) Common (total = 1774)
Whole-blood
RNA
Globin-reduced
RNA
Whole-blood
RNA
Globin-reduced
RNA
Whole-blood
RNA
Globin-reduced
RNA
\5% 264 256 3 9 3 5
5–25% 1063 1050 2 4 15 26
25–50% 1269 1242 2 2 79 106
50-75% 878 899 4 2 468 449
75–95% 135 162 5 0 940 918
[95% 0 0 1 0 269 270
Detectable probes were ranked according to their average, normalized expression intensities in both whole-blood and globin-reduced RNA
wtCFTR and delta508−CFTR traffic / Generic schema (norm and CF)
wtCFTR and delta508 traffic / Clathrin coated vesicles formation (norm and CF)
Ubiquinone metabolism
Transport
Translation
Transcription
Signal transduction
Regulation of lipid metabolism
Regulation of degradation of wt−CFTR
Regulation of degradation of deltaF508 CFTR in CF
Regulation of CFTR activity (norm and CF)
Proteolysis
Oxidative stress
Oxidative phosphorylation
NGF activation of NF−kB
Neurophysiological process
Muscle contraction
Mechanisms of CFTR activation by S−nitrosoglutathione (normal and CF)
Inhibitory action of Lipoxins on neutrophil migration
Immune response
G−protein signaling
Development
Cytoskeleton remodeling
Chemotaxis
Cell adhesion
Blood coagulation
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Fig. 2 Number of significantly enriched GeneGO pathways maps at a threshold of P B 0.001 in mouse whole-blood RNA (gray) and globin-
reduced RNA (black). The associated false discovery rate is less than 0.01 for a P value threshold less than or equal to 0.001
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one third of all probe sets present only in globin-reduced
RNA were ranked among the bottom 25% of all detectable
probe sets, while less than 4% were among the top 25%
(Table 1). In contrast, two thirds of the probe sets detected
in both whole-blood and globin-reduced blood RNA were
among the highest 25%. Again, this suggests that globin
reduction has a greater influence on the ability to detect
genes expressed at low levels in whole blood and supports
the idea that high levels of globin mRNA decrease detec-
tion sensitivity.
Gene set enrichment analysis of consistently present
probe sets in whole and globin-reduced RNA
In order to evaluate the potential of expression profiles
generated from globin-reduced mouse blood compared to
whole mouse blood, probe sets detected as present across
all samples in whole-blood RNA (n = 1791; Supplementary
Table 1) and globin-reduced RNA (n = 5383; Supple-
mentary Table 2) were imported into MetaCore for gene
set enrichment analysis. Globin reduction increased the
ability to detect genes in peripheral whole blood involved
in a variety of different biological pathways, most notably
development, g-protein signaling, and immune response
(Fig. 2). In total, the number of significantly enriched (P\
0.001) GeneGo Pathway Maps increased from 43 in whole-
blood samples to 107 in globin-reduced samples. Globin-
reduced samples were similarly enriched for GO biological
processes and molecular functions (Supplementary Figs. 1
and 2), including processes and molecular functions pre-
viously described as enriched in globin-reduced human
blood. This indicates that the globin expression signal
significantly weakens the ability to detect the expression
levels of many genes interrogated on microarrays, not
necessarily due to some biological connection with glo-
bin’s involvement in particular biological processes, but
Table 2 Top 25 statistically significant GeneGO disease categories in globin-reduced mouse blood RNA as compared to whole-blood RNA
GeneGO disease (by Biomarker) Globin-reduced RNA Whole-blood RNA McNemar test
Network objects P valuea Network objects P valuea
Hemic and lymphatic diseases 597/1927 1.02 9 10-11 251/1927 5.75 9 10-09 \2.2 9 10-16
Hematologic diseases 424/1316 1.04 9 10-10 195/1316 1.21 9 10-11 \2.2 9 10-16
Neoplasms 1571/5827 4.24 9 10-10 626/5827 3.45 9 10-09 \2.2 9 10-16
Anemia 135/344 2.25 9 10-09 73/344 2.24 9 10-11 2.13 9 10-12
Bone marrow diseases 256/748 2.60 9 10-09 114/748 1.25 9 10-07 \2.2 9 10-16
Spherocytosis, hereditary 13/13 1.50 9 10-08 9/13 3.16 9 10-07 NS
Tay-Sachs disease 11/11 2.40 9 10-07 8/11 8.45 9 10-07 NS
Gangliosidoses 12/13 5.99 9 10-07 8/13 5.53 9 10-06 NS
Anemia, hemolytic, congenital 66/153 6.44 9 10-07 40/153 1.81 9 10-09 9.44 9 10-07
Myelodysplastic syndromes 210/630 7.85 9 10-07 89/630 7.19 9 10-05 \2.2 9 10-16
Immunoproliferative disorders 459/1538 1.34 9 10-06 182/1538 5.51 9 10-04 \2.2 9 10-16
Lymphoproliferative disorders 458/1537 1.68 9 10-06 181/1537 7.34 9 10-04 \2.2 9 10-16
Neoplastic processes 280/887 2.21 9 10-06 144/887 1.75 9 10-11 \2.2 9 10-16
Gangliosidoses GM2 11/12 2.22 9 10-06 8/12 2.32 9 10-06 NS
Neoplasms by site 1091/3996 3.36 9 10-06 430/3996 1.65 9 10-04 \2.2 9 10-16
Breast neoplasms 539/1852 3.88 9 10-06 212/1852 1.09 9 10-03 \2.2 9 10-16
Anemia, hemolytic 77/194 4.03 9 10-06 47/194 1.08 9 10-09 1.19 9 10-07
Breast diseases 539/1853 4.17 9 10-06 212/1853 1.12 9 10-03 \2.2 9 10-16
Lymphatic diseases 464/1572 4.60 9 10-06 182/1572 1.63 9 10-03 \2.2 9 10-16
Leukemia, myeloid 193/586 5.52 9 10-06 80/586 5.11 9 10-04 \2.2 9 10-16
Leukemia, nonlymphocytic, acute 155/455 6.20 9 10-06 64/455 8.63 9 10-04 \2.2 9 10-16
Leukemia 339/1115 8.07 9 10-06 128/1115 1.17 9 10-02 \2.2 9 10-16
Thalassemia 29/55 9.49 9 10-06 18/55 1.71 9 10-06 2.57 9 10-03
Neoplasms by histologic type 1092/4027 1.59 9 10-05 442/4027 1.00 9 10-05 \2.2 9 10-16
RNA virus infections 195/603 1.80 9 10-05 77/603 4.21 9 10-03 \2.2 9 10-16
Network objects represent the proportion of disease-associated genes (biomarkers) identified per disease category, with the denominator
representing the number of objects assayed by the Affymetrix Mouse 430 2.0 array
a GeneGO hypergeometric model
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rather by virtue of their globin-relative signal strength
detectable via chip-based multiprobe hybridization. The
genes that happen to be affected by this phenomenon col-
lectively participate in a number of biologically meaningful
functions and processes. Thus, studies that do not reduce
globin yet investigate mouse blood gene expression as a
way of understanding disease processes are likely to fail to
implicate many important genes since their expression
levels are masked by globin.
The ability to detect genes previously implicated in dis-
ease was also significantly improved following globin
reduction. In general, both whole-blood and globin-reduced
blood RNA were significantly enriched for genes associated
with diseases involving all cell types found in peripheral
blood, including thrombocytes/platelets (thrombocytope-
nia), erythrocytes (anemia), myelocytes (myeloid leukemia),
and lymphocytes (lymphoma) (Table 2, Supplementary
Tables 4 and 5). Most importantly, the average potential to
identify expression levels of genes involved in a given dis-
ease or biological network more than doubled following
globin reduction as seen by the proportion of disease bio-
markers or disease-associated genes identified as present. To
test whether the removal of globin transcripts has a statisti-
cally significant effect on the proportion of genes identified,
significantly enriched GeneGo Diseases (P B 0.05) in either
whole-blood RNA or globin-reduced RNA were assessed
using the McNemar test. For the majority of significantly
enriched disease networks, the reduction of globin tran-
scripts significantly improved the ability to identify bio-
markers of disease (data not shown), including a variety of
nonhematologic-based diseases such as neuromuscular dis-
eases, neurodegenerative diseases, and chromosome aber-
rations (Table 3).
Comparisons to human whole blood
In order to evaluate the relevance of mouse blood gene
expression to human blood gene expression profiles, the
results of our mouse expression study were compared to
two human studies by gene set enrichment analysis (Lu
et al. 2009) (GSE2888; GSE16728) (Table 4). Of the 325
statistically significantly enriched GeneGo Pathway Maps
(P \0.001), 233 were significantly enriched in our mouse
study and the two human studies (Fig. 3) and include 97 of
the 107 pathways found to be significant after globin
reduction of mouse whole-blood RNA, including the
development and immune response pathways. Although
these results are not completely definitive due to differ-
ences in protocols used across each study, including dif-
ferent globin reduction methods, the number of samples,
and microarray designs, the overlap in significantly enri-
ched pathway categories suggests that genes expressed in
mouse peripheral blood reflect those expressed in human
blood.
Discussion
Our analysis of the effects of globin reduction on mouse
whole-blood-derived total RNA confirms the previously
observed increase in expression detection sensitivity and
overall detection rate in both humans and mice (Field et al.
2007; Whitley et al. 2005, 2007) and further emphasizes
the importance of globin reduction in evaluating biologi-
cally significant pathways and disease processes in mouse
models. Gene set enrichment analysis also indicates globin-
reduced mouse blood RNA is a reasonable and practical
Table 3 Nonhematologic-based diseases with a significantly improved proportion of gene expression levels detected in globin-reduced mouse
blood RNA as compared to whole mouse blood RNA
GeneGO disease (by biomarkers) Whole-blood
network objects
Globin-reduced
network objects
P valuea
Alzheimer’s disease 87/721 194/721 \2.20 9 10-16
Amyotrophic lateral sclerosis 19/167 54/167 9.08 9 10-9
Cerebellar ataxia 3/32 13/32 4.43 9 10-3
Dementia 97/829 226/829 \2.20 9 10-16
Down syndrome 21/133 41/133 2.15 9 10-5
Muscle hypertonia 5/48 21/48 1.77 9 10-4
Neurodegenerative diseases 161/1289 354/1289 \2.20 9 10-16
Ophthalmoplegia 1/34 12/34 2.57 9 10-3
Parkinson’s disease 38/283 64/283 9.44 9 10-7
Schizophrenia 106/752 208/752 \2.20 9 10-16
All diseases are significantly enriched with a GeneGO hypergeometric P B 0.05 in whole or globin-reduced blood RNA samples. Network
objects represent the proportion of disease-associated genes identified per disease category, with the denominator representing the number of
objects assayed by the Affymetrix Mouse 430 2.0 array
a McNemar test comparing the proportion of network objects identified before and after globin reduction
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model for the study of blood-based gene expression cor-
relates of human disease, as biological pathways signifi-
cantly enriched in globin-reduced mouse and human blood
overlap considerably.
However, globin reduction may not always be beneficial
or necessary in certain disease contexts. Our results suggest
that globin reduction appears to have little effect on the
ability to detect certain classes of biological pathways
(Fig. 2), while a small number of genes significantly
decrease in expression or fall below the limits of detection
following globin reduction, as noted in previous studies
(Field et al. 2007). A BLAST search did not identify sig-
nificant homology between the 17 probe sets whose
expression level-based presence was unique to whole-
blood RNA samples and the globin gene family, suggesting
that these probe sets are not specifically removed during
globin reduction but rather decrease in expression due to a
slight decline in RNA quality (Vartanian et al. 2009) or
other nonspecific effects. Nonetheless, these findings
indicate that globin-reduced, peripheral blood-based gene
expression profiling of relevant mouse models may reveal
unique patterns of gene expression relevant to human
disease and aid in the discovery of clinically significant
biomarkers.
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